Kangjian Miaomiao (Hangzhou) Pharmaceutical
Integrated platform for dental supplies and digital solutions
About Kangjian Miaomiao (Hangzhou) Pharmaceutical
Kangjian Miaomiao (Hangzhou) Pharmaceutical Co., Ltd., established on March 10, 2014, operates as a comprehensive service provider for the dental industry. The company was founded by Lin Xiaoping, who also serves as the legal representative and general manager.
The firm has developed an integrated ecosystem serving dentists and dental clinics through three primary offerings: a comprehensive online platform, a digital dentistry system, and customized dental products. Its B2B e-commerce platform, "Mei Miaomiao," launched in 2017, allows over 100,000 dental clinics to procure a wide range of products, including dental instruments, consumables, pharmaceuticals, and equipment. The business model focuses on leveraging internet technology and big data to improve supply chain efficiency and reduce transaction costs for dental practices.
In addition to its supply platform, Kangjian Miaomiao provides digital solutions through a DaaS (Data as a Service) model, featuring AI technology and cloud services to support clinical operations. The company also offers customized manufacturing services for products like removable orthodontic appliances, clear aligners, dentures, and pediatric silicone correctors, providing dentists with end-to-end solutions from data acquisition to design and production. To enhance logistics, the company has established six distribution centers across China.
The company has secured significant funding to fuel its growth. In October 2021, it raised a Series A round of ¥100 million. More recently, in June 2024, it completed a Series B financing of nearly ¥100 million from investors including Lanwan Capital, Kangde Lai, and Yika Capital, with existing shareholder KIP Capital also participating. These funds are allocated towards upgrading the IT infrastructure of its platform and enhancing its custom service capabilities.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2024 | $14M | $55M | Korea Investment Partners · Shanghai Intech Medical Devices · Xiaoka Capital · Shenzhen Blue Bay Capital | ↗ |
| SERIES AEquity / VC | Oct 2021 | $14M | $55M | Jacobson Pharma | ↗ |
Growth signals
Latest recorded traffic for Kangjian Miaomiao (Hangzhou) Pharmaceutical is 1.5K monthly website visits, up 212.5% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kangjian Miaomiao (Hangzhou) Pharmaceutical in its local ecosystem
The Kangjian Miaomiao (Hangzhou) Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- KIKey Innovation
Jacobson Pharma
Korea Investment Partners- SDShanghai Intech Medical Devices
Xiaoka Capital- SCShenzhen Blue Bay Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kangjian Miaomiao (Hangzhou) Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kangjian Miaomiao (Hangzhou) Pharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.